223 related articles for article (PubMed ID: 29287266)
1. Stability of infliximab solutions in different temperature and dilution conditions.
Tokhadze N; Chennell P; Le Basle Y; Sautou V
J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
[TBL] [Abstract][Full Text] [Related]
2. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
3. One-month stability study of a biosimilar of infliximab (Remsima
Vieillard V; Astier A; Sauzay C; Paul M
Ann Pharm Fr; 2017 Jan; 75(1):17-29. PubMed ID: 27659414
[TBL] [Abstract][Full Text] [Related]
4. Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.
Bardo-Brouard P; Vieillard V; Shekarian T; Marabelle A; Astier A; Paul M
Eur J Cancer; 2016 May; 58():8-16. PubMed ID: 26922168
[TBL] [Abstract][Full Text] [Related]
5. Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Paul M; Vieillard V; Jaccoulet E; Astier A
Int J Pharm; 2012 Oct; 436(1-2):282-90. PubMed ID: 22789912
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Guyader GL; Vieillard V; Paul M
J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
[TBL] [Abstract][Full Text] [Related]
7. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
8. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M; Gottar-Guillier M; Rossy E
Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
[TBL] [Abstract][Full Text] [Related]
10. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
11. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol.
Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS
J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046
[TBL] [Abstract][Full Text] [Related]
12. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.
Chen B; Bautista R; Yu K; Zapata GA; Mulkerrin MG; Chamow SM
Pharm Res; 2003 Dec; 20(12):1952-60. PubMed ID: 14725359
[TBL] [Abstract][Full Text] [Related]
13. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration.
Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A
Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582
[TBL] [Abstract][Full Text] [Related]
14. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering.
Legrand P; Dufaÿ S; Mignet N; Houzé P; Gahoual R
Anal Bioanal Chem; 2023 Jan; 415(1):179-192. PubMed ID: 36449030
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
[TBL] [Abstract][Full Text] [Related]
16. Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5 degrees C +/- 3 degrees C after Microwave Freeze-thaw Treatment.
Hecq JD; Rolin C; Godet M; Gillet P; Jamart J; Galanti LM
Int J Pharm Compd; 2015; 19(6):521-4. PubMed ID: 26891566
[TBL] [Abstract][Full Text] [Related]
17. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
Schüle S; Friess W; Bechtold-Peters K; Garidel P
Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
[TBL] [Abstract][Full Text] [Related]
18. Equilibrium studies of protein aggregates and homogeneous nucleation in protein formulation.
Kiese S; Pappenberger A; Friess W; Mahler HC
J Pharm Sci; 2010 Feb; 99(2):632-44. PubMed ID: 19548315
[TBL] [Abstract][Full Text] [Related]
19. Mechanically-induced aggregation of the monoclonal antibody cetuximab.
Lahlou A; Blanchet B; Carvalho M; Paul M; Astier A
Ann Pharm Fr; 2009 Sep; 67(5):340-52. PubMed ID: 19695370
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
